124 related articles for article (PubMed ID: 33130698)
1. [Interstitial Pneumonia Caused by Olaparib during Treatment of Breast Cancer-A Case Report].
Suzuki H; Oshino T; Hagio K; Takeshita T; Yamashita H
Gan To Kagaku Ryoho; 2020 Sep; 47(9):1351-1353. PubMed ID: 33130698
[TBL] [Abstract][Full Text] [Related]
2. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
[TBL] [Abstract][Full Text] [Related]
3. Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer.
Le D; Gelmon KA
Expert Rev Clin Pharmacol; 2018 Sep; 11(9):833-839. PubMed ID: 30118334
[TBL] [Abstract][Full Text] [Related]
4. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Kaufman B; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Steiner M; Loman N; Bowen K; Fielding A; Domchek SM
J Clin Oncol; 2015 Jan; 33(3):244-50. PubMed ID: 25366685
[TBL] [Abstract][Full Text] [Related]
5. Drug-induced interstitial lung disease caused by olaparib: three case reports and review of the Japanese Adverse Drug Event Report database and literature.
Ishimoto H; Sakamoto N; Kido T; Ozasa M; Tsutsui S; Mori M; Setoguchi D; Takemoto S; Obase Y; Ishimatsu Y; Tomonaga C; Matsumoto K; Morisaki S; Miura K; Mukae H
BMC Pulm Med; 2023 Aug; 23(1):289. PubMed ID: 37553592
[TBL] [Abstract][Full Text] [Related]
6. [A Case Report on the Effectiveness of Olaparib in a Patient with Recurrent Breast Cancer with Human Immunodeficiency Virus Infection].
Yabe S; Iwamoto N; Inokuchi T; Nara M; Saita C; Onishi M; Goto R; Yonekura R; Ishiba T; Honda Y; Miyamoto H; Aruga T
Gan To Kagaku Ryoho; 2020 Jul; 47(7):1089-1092. PubMed ID: 32668858
[TBL] [Abstract][Full Text] [Related]
7. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
[TBL] [Abstract][Full Text] [Related]
8. [A Case of Recurrent Breast Cancer with Improving Activities of Daily Living by Olaparib Treatment].
Nakagawa T; Oda G; Okamoto K; Ishikawa T; Wakana K; Oshima N
Gan To Kagaku Ryoho; 2021 Dec; 48(13):1556-1558. PubMed ID: 35046254
[TBL] [Abstract][Full Text] [Related]
9. [An Elderly Patient with Metastatic Breast Cancer Who Developed Severe Adverse Events such as Stomatitis and Interstitial Pneumonia after Everolimus plus Exemestane Treatment].
Sakiyama K; Yoshida T; Goto Y; Kimura M
Gan To Kagaku Ryoho; 2016 Jun; 43(6):753-5. PubMed ID: 27306814
[TBL] [Abstract][Full Text] [Related]
10. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.
Balmaña J; Tung NM; Isakoff SJ; Graña B; Ryan PD; Saura C; Lowe ES; Frewer P; Winer E; Baselga J; Garber JE
Ann Oncol; 2014 Aug; 25(8):1656-63. PubMed ID: 24827126
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
Lee CK; Scott C; Lindeman GJ; Hamilton A; Lieschke E; Gibbs E; Asher R; Badger H; Paterson R; Macnab L; Kwan EM; Francis PA; Boyle F; Friedlander M
Br J Cancer; 2019 Feb; 120(3):279-285. PubMed ID: 30655615
[TBL] [Abstract][Full Text] [Related]
13. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
14. [A Case of Metastatic Recurrent Breast Cancer Successfully with Olaparib in Late Line Therapy].
Soyama M; Kunihisa T; Shimada N; Suzuki H; Ookawa Y; Okamoto A; Yamamoto M; Miki M; Mizumoto S; Baba M; Tanino H
Gan To Kagaku Ryoho; 2021 Sep; 48(9):1153-1155. PubMed ID: 34521794
[TBL] [Abstract][Full Text] [Related]
15. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
16. Pneumocystis Pneumonia in a Patient with Ovarian Cancer Receiving Olaparib Therapy.
Himeji D; Tanaka GI; Shiiba R; Matsumoto R; Takamura K; Morishita H; Taniguchi S; Moriguchi S; Marutsuka K
Intern Med; 2022 Jan; 61(2):217-221. PubMed ID: 34248119
[TBL] [Abstract][Full Text] [Related]
17. Olaparib for the treatment of breast cancer.
Griguolo G; Dieci MV; Guarneri V; Conte P
Expert Rev Anticancer Ther; 2018 Jun; 18(6):519-530. PubMed ID: 29582690
[TBL] [Abstract][Full Text] [Related]
18. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
Moore KN; Monk BJ
Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
[TBL] [Abstract][Full Text] [Related]
19. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Moore K; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley W; Mathews C; Liu J; Lowe ES; Bloomfield R; DiSilvestro P
N Engl J Med; 2018 Dec; 379(26):2495-2505. PubMed ID: 30345884
[TBL] [Abstract][Full Text] [Related]
20. Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.
Lee JM; Peer CJ; Yu M; Amable L; Gordon N; Annunziata CM; Houston N; Goey AK; Sissung TM; Parker B; Minasian L; Chiou VL; Murphy RF; Widemann BC; Figg WD; Kohn EC
Clin Cancer Res; 2017 Mar; 23(6):1397-1406. PubMed ID: 27663600
[No Abstract] [Full Text] [Related]
[Next] [New Search]
